Navigation Links
Kemwell Appoints Dr. Ninad Deshpanday to Head Global R&D
Date:2/14/2013

BANGALORE, February 15, 2013 /PRNewswire/ --

Kemwell Biopharma Pvt. Ltd, a global pharmaceutical contract development and manufacturing company, announced that it has appointed Dr. Ninad Deshpanday as President of Research and Development.

Anurag Bagaria , Chairman and Managing Director of Kemwell said, "Dr. Deshpanday brings a unique combination of leadership skills and technical expertise in pharmaceutical development, as well as excellent business development skills with a very strong network of customers in the US, Europe and Asia. He will spearhead the R&D business for Kemwell as we continue to grow the geographical footprint and strategically position Kemwell into a leading Global Contract Services Provider."

Dr. Deshpanday has over 22 years' experience of diverse international experience in the pharmaceutical industry (US + India). This includes pharmaceutical development activities for NDAs, specialty drug delivery based 505(b)(2) products, including Oral and Transdermal, and complex Generic products, with several F2Fs and PIVs. He also has rich experience in Technical and Business Development

Prior to joining Kemwell, he was President of Pharmaceutical R&D at Lupin, in Pune, India since Nov. 2007, with leadership responsibilities for formulations, analytical, and BA/BE activities. Before joining Lupin, Dr. Deshpanday was Vice President of Business Development at AAIPharma in RTP, NC, with responsibilities for sales and marketing activities for their CM&C functions; Vice President for Drug Product Development for Synta Pharmaceuticals, with responsibilities for all CM&C activities; and Technical Business Director for the Pharmaceutics division of Cardinal Health. Dr. Deshpanday earned his Doctorate in Pharmaceutics from the University of S. Carolina in 1990, and has an M. Pharm. and B. Pharm. from LM College of Pharmacy in Ahmedabad, India.

About Kemwell Biopharma Pvt. Ltd.

Kemwell Biopharma Pvt. Ltd, headquartered in Bangalore, India is a pure-play global contract development and manufacturing company. The company manufactures and develops pharmaceuticals for some of the world's top pharmaceutical companies, including GlaxoSmithKline, Bayer, Novartis and Pfizer. Kemwell is one of India's largest contract manufacturers of pharmaceuticals with over 30 years' experience. The company employs more than 1000 employees worldwide and has seven production facilities, five in India and two in Sweden. Kemwell is an approved pharmaceutical manufacturer in over 80 countries including the American, European, Japanese and Indian markets. Read more about Kemwell on www.kemwellbiopharma.com.

Primary Media Contact: Karan Bagaria , karan.bagaria@kemwellpharma.com, 91-80-39286200

Secondary Media Contact: Bhaskar Viswanathan , bhaskar.viswanathan@kemwellpharma.com, 91-80-39286200


'/>"/>
SOURCE Kemwell Biopharma Pvt Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Avantium Appoints Jonathan Wolfson to its Supervisory Board
2. Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
3. PCI Appoints Jose Solorio-Ruiz, MBA, Manager of West Coast Operations
4. Advanced Cell Diagnostics Appoints Evangeline Gonzalez as Chief Commercial Officer
5. California Healthcare Institute Appoints Allergan CEO Chairman of the Board, Elects New Board Members
6. uniQure Appoints Philip Astley-Sparke President US
7. HealthEconomics.Com Appoints New Director of Information Technology and Operations
8. TransCelerate BioPharma Inc. Appoints Dalvir Gill as Chief Executive Officer
9. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
10. Lakewood-Amedex Inc. Appoints Marie E. Knight To Its Board Of Directors
11. Amarantus Appoints Super Bowl Champion Toi Cook to Board of Advisors to Advance TBI Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Wells, CA (PRWEB) , ... January 21, 2017 ... ... in our ongoing endeavors to bring to market a pioneering medical device for ... O’Rourke, has signed an engagement contract with Emergo, a global regulatory consultancy that ...
(Date:1/21/2017)... 21, 2017   Boston Biomedical , an industry ... target cancer stemness pathways, today presented data from two ... the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal ... In a Phase Ib/II study of ... inhibit cancer stemness pathways by targeting STAT3 – colorectal ...
(Date:1/20/2017)... , January 20, 2017 ... cancer is one of leading causes of death worldwide. ... Although the number of cancer related deaths increased gradually ... Rising in incidence rate of various cancers continues to ... a research report by Global Market Insights, Inc. cancer ...
(Date:1/19/2017)... and HOUSTON , Jan. 19, ... today announced the formation of its Medical/Clinical Advisory ... and industry veterans who enhance the range and ... accelerates development of its novel prenatal diagnostic tests.  ... clinical and strategic guidance for the company,s product ...
Breaking Biology Technology:
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... office of the future.  1,000 participants were simply asked which ... months which we may consider standard issue.  Insights on what ... 2017 were also gathered from futurists and industry leaders including ... James Canton .  Some of ...
(Date:1/6/2017)... , Jan. 5, 2017  SomaLogic announced today ... Life Alliance" established by iCarbonX, the ... build a "Global Digital Health Ecosystem that can ... combination of individual,s biological, behavioral and psychological data, ... between the companies, SomaLogic will provide proteomics data ...
(Date:12/22/2016)... -- As part of its longstanding mission to improve genetic literacy ... released its latest children,s book, titled The One ... topics of inheritance and variation of traits that are part ... school classrooms in the US. The book ... Killoran , whose previous book with 23andMe, You ...
Breaking Biology News(10 mins):